Vector transmission of leishmania abrogates vaccine-induced protective immunity.
Numerous experimental vaccines have been developed to protect against the cutaneous and visceral forms of leishmaniasis caused by infection with the obligate intracellular protozoan Leishmania, but a human vaccine still does not exist. Remarkably, the efficacy of anti-Leishmania vaccines has never been fully evaluated under experimental conditions following natural vector transmission by infected sand fly bite. The only immunization strategy known to protect humans against natural exposure is "leishmanization," in which viable L. major parasites are intentionally inoculated into a selected site in the skin. We employed mice with healed L. major infections to mimic leishmanization, and found tissue-seeking, cytokine-producing CD4+ T cells specific for Leishmania at the site of challenge by infected sand fly bite within 24 hours, and these mice were highly resistant to sand fly transmitted infection. In contrast, mice vaccinated with a killed vaccine comprised of autoclaved L. major antigen (ALM)+CpG oligodeoxynucleotides that protected against needle inoculation of parasites, showed delayed expression of protective immunity and failed to protect against infected sand fly challenge. Two-photon intra-vital microscopy and flow cytometric analysis revealed that sand fly, but not needle challenge, resulted in the maintenance of a localized neutrophilic response at the inoculation site, and removal of neutrophils following vector transmission led to increased parasite-specific immune responses and promoted the efficacy of the killed vaccine. These observations identify the critical immunological factors influencing vaccine efficacy following natural transmission of Leishmania.
Peters
Nathan C
NC
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Kimblin
Nicola
N
Secundino
Nagila
N
Kamhawi
Shaden
S
Lawyer
Phillip
P
Sacks
David L
DL
D000818:Animals; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured; D018899:CpG Islands / Q000276:immunology; D004195:Disease Models, Animal; D004817:Epidermis / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D007249:Inflammation / Q000276:immunology; D007303:Insect Vectors / Q000469:parasitology; D018320:Leishmania major / Q000276:immunology*; D007896:Leishmaniasis / Q000276:immunology* / Q000517:prevention & control / Q000635:transmission; D054332:Leishmaniasis Vaccines / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009504:Neutrophils / Q000276:immunology; D011576:Psychodidae / Q000469:parasitology*; D018709:Statistics, Nonparametric; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology
D054332:Leishmaniasis Vaccines; D014613:Vaccines, Attenuated